Regina has over 15 years of corporate finance experience working with emerging technology and healthcare companies.
Starting out as a venture capital deal professional at GE Equity and moving on to management roles at venture backed and privately held healthcare companies, Regina gained breadth and depth of experience with the issues facing high growth technology enabled healthcare services businesses. As a Vice President and deal team member at GE Equity, a $2.0B direct investments unit of General Electric, Regina made investments in leading internet-technology companies of the first .com wave and served as a board observer.
Regina joined Comprehensive Neuroscience as SVP of Finance and Strategic Planning, a venture capital portfolio company that conducted clinical trials for major pharmaceutical companies on a national scale and commercialized a novel technology-based care management program for psychiatric populations through its Care Management Technologies division, which was widely adopted by 25 states’ Medicaid through partnership with Lilly, and leading Medicare plans including Humana. Regina was also CFO at Kurron & Co., a NYC based hospital management company, where she provided financial stewardship to independent hospitals adapting to state Commission on Health Care Facilities reforms.
Prior to joining Cecelia Health, Regina was a consultant to healthcare innovators including Otsuka Pharmaceutical where she contributed to the company’s entry into digital therapeutics and its alliance with Click Therapeutics, and FleurirABX, a specialty pharmaceutical company developing new treatments for drug resistant infectious diseases.
Regina holds an MBA from Columbia Business School and a BS in Accounting from St. John’s University.
Current role